Augmedix, Inc. (NASDAQ:AUGX) Insider Sells $129,895.64 in Stock

Augmedix, Inc. (NASDAQ:AUGXGet Free Report) insider Ian Shakil sold 31,994 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $4.06, for a total value of $129,895.64. Following the completion of the transaction, the insider now owns 187,666 shares of the company’s stock, valued at approximately $761,923.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ian Shakil also recently made the following trade(s):

  • On Monday, April 1st, Ian Shakil sold 58,978 shares of Augmedix stock. The shares were sold at an average price of $3.91, for a total value of $230,603.98.

Augmedix Trading Up 4.0 %

Shares of AUGX stock opened at $4.18 on Thursday. Augmedix, Inc. has a twelve month low of $1.50 and a twelve month high of $6.25. The firm has a 50-day moving average price of $4.21 and a 200 day moving average price of $4.87. The company has a current ratio of 2.41, a quick ratio of 2.41 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $203.73 million, a price-to-earnings ratio of -9.29 and a beta of -0.16.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AUGX. Portside Wealth Group LLC acquired a new position in shares of Augmedix during the 2nd quarter valued at about $286,000. Tucker Asset Management LLC acquired a new position in shares of Augmedix during the 2nd quarter valued at about $172,000. Vontobel Holding Ltd. increased its stake in shares of Augmedix by 439.7% during the 3rd quarter. Vontobel Holding Ltd. now owns 173,209 shares of the company’s stock valued at $892,000 after acquiring an additional 141,113 shares during the last quarter. Legato Capital Management LLC acquired a new position in shares of Augmedix during the 3rd quarter valued at about $840,000. Finally, Taylor Frigon Capital Management LLC acquired a new position in shares of Augmedix during the 3rd quarter valued at about $438,000. Institutional investors and hedge funds own 87.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Evercore ISI cut their target price on shares of Augmedix from $6.50 to $4.50 and set an “in-line” rating for the company in a research note on Tuesday, March 19th. B. Riley assumed coverage on shares of Augmedix in a research note on Wednesday. They issued a “buy” rating and a $5.50 target price for the company. Finally, Maxim Group cut their target price on shares of Augmedix from $6.50 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, March 19th.

Get Our Latest Stock Report on Augmedix

Augmedix Company Profile

(Get Free Report)

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.

Further Reading

Receive News & Ratings for Augmedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Augmedix and related companies with MarketBeat.com's FREE daily email newsletter.